Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis.

Comparative Efficacy of Acupuncture Combined With Chinese Herbal Cream and Acupuncture Combined With Calcipotriol for Plaque Psoriasis.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07410793

Enrollment

Registered

2026-02-13

Start date

2026-02-09

Completion date

2027-02-08

Last updated

2026-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque Type Psorisis

Keywords

plaque psoriasis, acupuncture, chinese herbal cream, calcipotriol

Brief summary

Clinical trial which compares 2 treatment methods (1) Acupunture with a Chinese Herbal Cream and (2) Acupuncture with the standard treatment "calcipotriol" for patients with plaque psoriasis.

Interventions

PROCEDUREAcupuncture

Bai-Hui (GV20), Fei-Shu (BL13), Ge-Shu (BL-17), Qu-Chi (LI11), Zu-San-Li (ST36), He-Gu (LI4), Tai-Chong (LR3), San-Yin-Jiao (SP6), Wei-Zhong (BL40)

DRUGCalcipotriol 0.005% ointment

Calcipotriol 0.005% ointment

DRUGChinese herb cream

Main API : Sophora flavescens Ait. (Ku-Shen), Cnidium monnieri (L.) Cuss. (She-Chuang-Zi), Prunus mume (Sieb.) Sieb.et Zucc. (Wu-Mei), Dictamnus dasycarpus Turcz. (Bai-Xian-Pi), Rheum palmatum L. (Da-Huang)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Plaque psoriasis on skin, scalp, or nails * Not receive any psoriasis treatment at least 4 weeks prior to the study * ≤10% body surface area (BSA), PASI≤10, DLQI≤10

Exclusion criteria

* Pregnancy and lactation * Other type of psoriasis i.e. Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis * Uncontrollable diseases i.e. CVS, liver, kidney, cancer * Using anticoagulants i.e. Aspirin, Warfarin, Clopidogrel, Dabigatran, Riavaraxaban, Apixaban, Heparin * Treated with psoriasis biologic agents in the past 6 months * Needle phobia * Receiving immunosuppresive agents i.e. systemic corticosteroid, NSAIDs, chemotherapeutic agents * Participating in other clinical study

Design outcomes

Primary

Measure	Time frame
Psoriasis Area and Severity Index, PASI score	8 weeks

Secondary

Measure	Time frame
Dermatology Life Quality Index (DLQI)	8 weeks

Countries

Thailand

Contacts

CONTACTDr.Sinee Tantasatityanon, TCMD, PhD

sinee.tan@mfu.ac.th+66818092078

CONTACTAsst.Prof.Dr.Chakree Chumvisoot Wattanasiri, RPh, PhD

chakree.wat@mfu.ac.th

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026